Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

NCT01933334 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01933334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01933334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
September 30, 2014
Enrollment
63 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis